Janssen

Janssen

Janssen

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Janssen

Address

Lazio, Italy

Contact

n.a.

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Janssen

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Janssen last news

26/01/2024

Finetuning 'beany, earthy, and bitter' off notes in plant-based meat alternatives

Off notes or flavour challenges in meat-free products has been a headache for the food industry for years, but new research could put that problem to bed once and for all.

26/01/2024

J&J promotes prostate cancer genetic connections in new BRCA campaign

Many people are familiar with BRCA, or breast cancer gene 1 and 2, mutations in breast cancer, but they can also play a role in prostate cancer. J&J is tackling the subject in new communications and adding light-hearted humor with its "Dad Genes" website. On BRCAInMen.com, men, boys and a few women wear high-waisted and belted baggy denim to make the visual jeans/genes homonym pun. While the new work is unbranded, J&J's oral prostate cancer combination drug Akeega (niraparib and abiraterone acetate) was approved in August to treat people with BRCA-positive metastatic castration-resistant prostate cancer. The campaign is part of a broader push by J&J Innovative Medicine, the pharma division formerly called Janssen, to drum up awareness about family genetic connections in prostate cancer and encourage screening. Tyrone Brewer "We explored various creative ideas to illustrate the concept of traditions being passed along, and the analogy of 'dad jeans/genes' resonated," Tyrone Brewer, J&J Innovative Medicine's president of US oncology, said in an email. "Given that information about genetic mutations and testing can be overwhelming for many patients and caregivers, infusing a hint of playfulness helped ease comprehension and enabled a better understanding." About 60% of prostate cancers are caused by genetic factors, and BRCA-mutation prostate cancers tend to be more aggressive and have a higher resistance to standard of care chemotherapy treatment, he said. J&J social media videos running on Facebook and Instagram explain the BRCA1 and BRCA2 connections, advising screening and more open conversations with physicians, family and friends around assessing risk. The "Dad Genes" website also explains the mutations in detail and offers testing and support resources. "Genetic mutation status is an important piece to the puzzle that can shift the treatment approach as it guides personalized treatment options targeting their specific genetic mutation(s) vs standard of therapy (chemo)," Brewer said, adding that "testing not only benefits the patient, but also the patient's family by informing them of their inherited risk of developing various cancers in advance."

26/01/2024

Year in Review: Top Regulatory Developments of 2023

​​​​​​​As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023. Below are some of the top regulatory developments from 2023.... By: Goodwin